Two [25, 28] articles (2 cohorts) reported median EFS with IDH inhibitors monotherapy in R/R IDH-mutated AML, and our pooled median EFS was 4.73 months [95% CI 4.01–5.45, I2 = 0%]. This evidence concerns the gene IDH2 and acute myeloid leukemia.